Laura Bonanno
Laura Bonanno is an expert in Oncology at Azienda Ospedaliera di Padova (Italy). As of October 2026, ScienceLeadR ranks Laura Bonanno in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Laura Bonanno has authored 263 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 11 of them ongoing. SLR score: 1,353 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Biochemistry - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2010 - 2026
Number : 263
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. PMID 42929675 — progression-free survival, disease progression, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, therapeutics | N Engl J Med Top journal | 2026 | 0 |
| Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. PMID 42929693 — cells, pemetrexed, progression-free survival, neoplasms, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, therapeutics | N Engl J Med Top journal | 2026 | 0 |
| Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. PMID 42654023 — cells, lung, antigens, surface, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics, lung diseases, interstitial | Pharmaceutics | 2026 | 0 |
| Comparing Real-Time PCR and Amplicon-Based NGS for Routine EGFR Liquid Biopsy Profiling. PMID 42587629 — biopsy, lung neoplasms, liquid biopsy, mutation, real-time polymerase chain reaction, egfr mutation | Diagnostics (Basel) | 2026 | 0 |
| Feasibility of Minimally Invasive Surgery After Chemo-Immunotherapy in Locally Advanced and Oligometastatic NSCLC: Technical Aspects and Surgical Outcomes. PMID 42512310 — lung, minimally invasive surgical procedures, carcinoma, non-small-cell lung, reoperation, immunotherapy, morbidity | Cancers (Basel) | 2026 | 0 |
Clinical Studies 27
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases 2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib | Phase 3 | Active not recruiting | 2021 |
| A trial to learn how effective and safe datopotamab deruxtecan (Dato DXd) is compared to docetaxel and how well Dato DXd works in adults with advanced or metastatic TROP2 positive non squamous non small cell lung cancer (NS NSCLC) 2024-520101-39-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma | Phase 3 | Not yet recruiting | 2026 |
| A Randomized Double Blind Placebo Controlled MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004 TAB004) as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy 2023-507097-41-01 — cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics | Phase 3 | Active not recruiting | 2025 |
| A Study of Dato DXd in Combination With Durvalumab and Carboplatin for First line Treatment of Advanced NSCLC Without Actionable Genomic Alterations 2023-505993-14-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, carboplatin, chemotherapy | Phase 3 | Active not recruiting | 2023 |
| A Phase 2b Open Label Two cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First Line Treatment or Subcutaneous Amivantamab in Combination with Platinum Based Chemotherapy as Second line Treatment for Common EGFR Mutated Locally Advanced or Metastatic Non Small Cell Lung Cancer 2025-520730-28-00 — cells, lung, neoplasms, cohort studies, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map